BACKGROUND: Mitral regurgitation (MR) is a frequent finding in patients with aortic stenosis (AS). The objective of this study is to assess the change in MR severity following transcatheter aortic valve implantation (TAVI). METHODS: MR changes were assessed by comparing transthoracic echocardiography before and after the procedure. RESULTS: The prosthetic aortic valve was successfully implanted in 65 patients. The number of patients with pre-procedure MR was reduced from 58 (85.3%) to 43 (63.2%) (p < 0.001). Vena contracta width was decreased from 0.47 ± 0.28 to 0.25 ± 0.21, (p = 0.043). About 59.4% (19/32) of those who had moderate to severe MR and 85.7% (12/14) of those with severe MR experienced a significant improvement in MR after the procedure (p < 0.001). Improvement in MR was independent of prosthetic valve type with 54.2% in CoreValve and 43.9% in Edwards SAPIEN, p = 0.424; valve sizes were 25.8 ± 1.9 in those who improved vs. 25.0 ± 1.9 mm in those who did not improve, p = 0.105; femoral approach was 51.2% and apical approach was 41.7%, p = 0.457; MR etiology was 48.1% in organic and 48.6% in functional, p = 0.968; and operative risk was 50.0% in EuroScore >20 and 48.6% in EuroScore <20, p = 0.356. CONCLUSIONS: TAVI is associated with a significant improvement in MR, especially in severe types. The lack of influence of MR improvement by the etiology of MR, the type of valve implanted, and the operative risk need to be confirmed in a larger multi-center study.
BACKGROUND:Mitral regurgitation (MR) is a frequent finding in patients with aortic stenosis (AS). The objective of this study is to assess the change in MR severity following transcatheter aortic valve implantation (TAVI). METHODS: MR changes were assessed by comparing transthoracic echocardiography before and after the procedure. RESULTS: The prosthetic aortic valve was successfully implanted in 65 patients. The number of patients with pre-procedure MR was reduced from 58 (85.3%) to 43 (63.2%) (p < 0.001). Vena contracta width was decreased from 0.47 ± 0.28 to 0.25 ± 0.21, (p = 0.043). About 59.4% (19/32) of those who had moderate to severe MR and 85.7% (12/14) of those with severe MR experienced a significant improvement in MR after the procedure (p < 0.001). Improvement in MR was independent of prosthetic valve type with 54.2% in CoreValve and 43.9% in Edwards SAPIEN, p = 0.424; valve sizes were 25.8 ± 1.9 in those who improved vs. 25.0 ± 1.9 mm in those who did not improve, p = 0.105; femoral approach was 51.2% and apical approach was 41.7%, p = 0.457; MR etiology was 48.1% in organic and 48.6% in functional, p = 0.968; and operative risk was 50.0% in EuroScore >20 and 48.6% in EuroScore <20, p = 0.356. CONCLUSIONS: TAVI is associated with a significant improvement in MR, especially in severe types. The lack of influence of MR improvement by the etiology of MR, the type of valve implanted, and the operative risk need to be confirmed in a larger multi-center study.
Authors: F Roques; S A Nashef; P Michel; E Gauducheau; C de Vincentiis; E Baudet; J Cortina; M David; A Faichney; F Gabrielle; E Gams; A Harjula; M T Jones; P P Pintor; R Salamon; L Thulin Journal: Eur J Cardiothorac Surg Date: 1999-06 Impact factor: 4.191
Authors: Francesco Saia; Cinzia Marrozzini; Gianni Dall'Ara; Vincenzo Russo; Sofia Martìn-Suàrez; Carlo Savini; Paolo Ortolani; Tullio Palmerini; Nevio Taglieri; Barbara Bordoni; Emanuele Pilato; Roberto Di Bartolomeo; Angelo Branzi; Antonio Marzocchi Journal: J Cardiovasc Med (Hagerstown) Date: 2010-10 Impact factor: 2.160
Authors: Alec Vahanian; Helmut Baumgartner; Jeroen Bax; Eric Butchart; Robert Dion; Gerasimos Filippatos; Frank Flachskampf; Roger Hall; Bernard Iung; Jaroslaw Kasprzak; Patrick Nataf; Pilar Tornos; Lucia Torracca; Arnold Wenink Journal: Eur Heart J Date: 2007-01-26 Impact factor: 29.983
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Alain Cribier; Helene Eltchaninoff; Assaf Bash; Nicolas Borenstein; Christophe Tron; Fabrice Bauer; Genevieve Derumeaux; Frederic Anselme; François Laborde; Martin B Leon Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: Philippe Unger; Danièle Plein; Guy Van Camp; Bernard Cosyns; Agnès Pasquet; Valérie Henrard; Didier de Cannière; Christian Melot; Luc A Piérard; Patrizio Lancellotti Journal: Am J Cardiol Date: 2008-09-11 Impact factor: 2.778
Authors: Nader Moazami; Michael D Diodato; Marc R Moon; Jennifer S Lawton; Michael K Pasque; Rachel L Herren; Tracey J Guthrie; Ralph J Damiano Journal: J Card Surg Date: 2004 Sep-Oct Impact factor: 1.620
Authors: R Jansen; A M Wind; M J Cramer; F Nijhoff; P Agostoni; F Z Ramjankhan; W J Suyker; P R Stella; S A J Chamuleau Journal: Int J Cardiovasc Imaging Date: 2018-03-10 Impact factor: 2.357
Authors: Faisal Owdah Alatawi; Reda A Abuelatta; Ahmed B AlAhmedi; Ibraheem H Alharbi; Saleh S Alghamdi; Amal A Sakrana; Osama A Alamodi; Hesham A Naeim Journal: Ann Saudi Med Date: 2018 May-Jun Impact factor: 1.526